Pfizer Inc. announced on June 25, 2026, that the FDA approved IBRANCE (palbociclib) for an expanded indication. This approval covers IBRANCE in combination with other therapies for the maintenance treatment of adults with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-positive (HER2+) locally advanced or metastatic breast cancer.
The Phase 3 PATINA trial provided the basis for this regulatory decision. Results demonstrated a 24% reduction in the risk of disease progression or death when adding IBRANCE to the treatment regimen.
IBRANCE is now the first and only CDK4/6 inhibitor approved for HR+ metastatic breast cancer patients regardless of HER2 status. This expansion significantly broadens the drug's market potential.
Separately, Pfizer declared a $0.43 dividend for the third quarter of 2026.